Dabigatran link to coronary events

New anticoagulant dabigatran is associated with an increased risk of acute coronary events compared with older medications such as warfarin, research finds.

A meta-analysis of seven trials involving 30,500 patients found those taking dabigatran (Pradaxa) faced a 33% higher risk of MI or acute coronary syndrome compared with patients on treatments including adjusted-dose warfarin, enoxaparin or placebo.

Writing in the Archives of Internal Medicine, the review authors